

# Wei Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6557260/publications.pdf>

Version: 2024-02-01

26  
papers

1,265  
citations

687363

13  
h-index

552781

26  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1540  
citing authors

#	ARTICLE	IF	CITATIONS
1	Î, Defensins Protect Cells from Infection by Herpes Simplex Virus by Inhibiting Viral Adhesion and Entry. <i>Journal of Virology</i> , 2004, 78, 5147-5156.	3.4	241
2	Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. <i>Nature Immunology</i> , 2005, 6, 995-1001.	14.5	235
3	Retrocyclin, an Antiretroviral Î-Defensin, Is a Lectin. <i>Journal of Immunology</i> , 2003, 170, 4708-4716.	0.8	187
4	Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	102
5	Japanese Encephalitis Virus Activates Autophagy as a Viral Immune Evasion Strategy. <i>PLoS ONE</i> , 2013, 8, e52909.	2.5	70
6	Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. <i>Antiviral Research</i> , 2017, 141, 140-149.	4.1	51
7	Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. <i>Journal of Virology</i> , 2018, 92, .	3.4	48
8	Quantitative Proteomic Analysis of Mosquito C6/36 Cells Reveals Host Proteins Involved in Zika Virus Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	47
9	The ubiquitin-proteasome system is essential for the productive entry of Japanese encephalitis virus. <i>Virology</i> , 2016, 498, 116-127.	2.4	44
10	Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III. <i>Antiviral Research</i> , 2014, 104, 7-14.	4.1	38
11	Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	31
12	Structure-function relationship of the mammarenavirus envelope glycoprotein. <i>Virologica Sinica</i> , 2016, 31, 380-394.	3.0	20
13	Screening of Botanical Drugs against Lassa Virus Entry. <i>Journal of Virology</i> , 2021, 95, .	3.4	17
14	Activation of the RLR/MAVS Signaling Pathway by the L Protein of Mopeia Virus. <i>Journal of Virology</i> , 2016, 90, 10259-10270.	3.4	15
15	Novel neutralizing monoclonal antibodies against Junin virus. <i>Antiviral Research</i> , 2018, 156, 21-28.	4.1	15
16	Inhibition of Na <sup>+</sup> /K <sup>+</sup> ATPase blocks Zika virus infection in mice. <i>Communications Biology</i> , 2020, 3, 380.	4.4	15
17	Structure-activity relationship optimization for lassa virus fusion inhibitors targeting the transmembrane domain of GP2. <i>Protein and Cell</i> , 2019, 10, 137-142.	11.0	14
18	Development of horse neutralizing immunoglobulin and immunoglobulin fragments against JunÃn virus. <i>Antiviral Research</i> , 2020, 174, 104666.	4.1	14

#	ARTICLE	IF	CITATIONS
19	Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response. <i>Virologica Sinica</i> , 2021, 36, 774-783.	3.0	12
20	Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. <i>Viruses</i> , 2022, 14, 353.	3.3	11
21	Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity. <i>Virologica Sinica</i> , 2021, 36, 273-280.	3.0	9
22	Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters. <i>Antiviral Research</i> , 2022, 204, 105365.	4.1	7
23	Mechanism through Which Retrocyclin Targets Flavivirus Multiplication. <i>Journal of Virology</i> , 2021, 95, e0056021.	3.4	6
24	Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library. <i>Frontiers in Microbiology</i> , 2021, 12, 793519.	3.5	5
25	RNA Interference Screening Reveals Requirement for Platelet-Derived Growth Factor Receptor Beta in Japanese Encephalitis Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	4
26	Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library. <i>Antiviral Research</i> , 2022, 197, 105230.	4.1	4